Neoleukin Therapeutics Inc (NASDAQ:NLTX)
| 0.8038 BATS BZX Real-Time Price As of Jun 02 |  0.00 / 0.00%Today’s Change | 0.38 Today|||52-Week Range 1.34 | +57.92% Year-to-Date |
| SECTOR Health Technology | INDUSTRY Biotechnology | MARKET CAP $34.4M |
Company Description
Neoleukin Therapeutics, Inc. operates as a biopharmaceutical company, which computational methods to design de novo protein therapeutics. The firm address significant medical needs in oncology, inflammation, and autoimmunity. Its lead product candidate, NL-201, is a combined IL-2 and IL-15 agonist designed to eliminate alpha receptor binding. The company was founded by Daniel-Adriano Silva, Carl Walkey, and Umut Ulge in December 2003 and is headquartered in Seattle, WA.
Contact Information
Neoleukin Therapeutics, Inc. 188 East Blaine Street Seattle Washington 98102 |
Employees
Shareholders
| Other institutional | 32.20% |
| Mutual fund holders | 3.60% |
| Individual stakeholders | 28.09% |
Top Executives
| Donna M. Cochener-Metcalfe | CEO, Secretary, SVP-Legal & General Counsel |
| Sean Smith | Chief Financial Officer |
